Golden, Colorado (BUSINESS WIRE)—Reven Holdings, Inc. (“Reven”) is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, cardiovascular and metabolic disorders, viral illnesses—including COVID-19—and inflammatory disorders.
The lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) is being developed for both treatment of COVID-19 as well as critical limb threatening ischemia (CLTI), a cardiovascular condition associated with a high risk of limb amputation, myocardial infarct and stroke. Reven has an active Investigational New Drug (IND) with the United States Food and Drug Administration for clinical evaluation of the safety and efficacy of RJX for the CLTI indication and is pursuing a clinical development plan.
Reven today announced that it received a formal Notice of Allowance from the US Patent and Trademark Office regarding its patent application entitled: “Compositions and Methods for the Prevention and Treatment of Cardiovascular Disease” (US Patent Application No. 15/692,694).
Henk van Wyk, the lead inventor and Chief Scientist commented: “I am very excited and honored about this favorable disposition regarding the patent application for my invention. I hope that RJX can provide the foundation for effective and much needed new treatment modalities against difficult to treat diseases.” “We believe that the RJX platform has therapeutic impact potential and Reven’s strong patent portfolio reflects both our commitment to its commercial development and its novelty”, added Peter Lange, Reven’s CEO.
“I am delighted to have the opportunity to work with Henk as part of Reven’s leadership team. We are diligently working to advance the RJX clinical trial program with the vision of bringing a new treatment option to high-risk CLTI patients who are in urgent need for therapeutic innovations.”, added Michael Volk, co-founder and Chief Strategy Officer of Reven.
About Rejuveinix (RJX)
RJX is an intravenous (IV) formulation of physiologically compatible compounds that along with CLTI, is also being developed for treatment of sepsis, including COVID-19 patients with viral sepsis and acute respiratory distress syndrome (ARDS). The clinical safety and tolerability of RJX was confirmed in a recently completed double blind, placebo-controlled Phase 1 dose-escalation study in healthy volunteers (ClinicalTrials.gov Identifier: NCT03680105).
About Reven Holdings, Inc.
Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado based operating company Reven, LLC, is a biopharmaceutical company. Reven’s vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases. Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world. Its primary product, RJX, targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering from Peripheral Arterial Disease (PAD) and other cardiovascular related medical conditions.
Reven’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “on-track”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, “estimate,” “intend,” “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various disease indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing market competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates, and unexpected litigation or other disputes. These risks are not exhaustive; the company faces known and unknown risks, including the risk factors described in the company’s periodic SEC filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information regarding future events, or otherwise.
Contact
Natalie Pizzimenti, Medical Scientific Liaison
+1 (586)– 242-9590
natalie.pizzimenti@reven.com